GSK transfers Ultiva to Aspen in Australia

GlaxoSmithKline Australia Pty Ltd (GSK) is formally transferring Ultiva (remifentanil), an anaesthetic, to Aspen Pharmacare Australia Pty Ltd (Aspen).  In Australia, distribution will be managed by Aspen effective from 31st May 2017.

This decision reflects the global agreement to divest GSK’s anaesthesia portfolio to Aspen in all countries (excluding the US and Canada which has been previously divested) which completed on 28 February 2017.

The agreement better aligns GSK with our strategy of simplification and allows greater focus on our respiratory and primary care medicines, as well as our vaccines.

Please note that Ultiva is currently out of stock in Australia and remains unavailable until 2018. For enquiries or updates to supply, please contact Aspen as per contact details listed below.

 

Aspen Customer Care Australia

Phone: 1300 659 646

 

 

 

 

Media Enquiries:

GSK - Kim O’Donohue, 0477 322 431